K2 PRINCIPAL FUND L.P. 13D and 13G filings for TCR2 Therapeutics Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2023-02-08 5:51 pm Sale | 2022-12-31 | 13G | TCR2 Therapeutics Inc. TCRR | K2 PRINCIPAL FUND L.P. | 0 0.000% | -1,950,628 (Position Closed) | Filing |
| 2022-08-31 6:13 pm Purchase | 2022-08-26 | 13G | TCR2 Therapeutics Inc. TCRR | K2 PRINCIPAL FUND L.P. | 1,950,628 5.050% | 1,950,628 (New Position) | Filing |